Is Iovance Biotherapeutics Stock a Buy Now?

Let's find out if this biotech can keep up its recent momentum.Is this the start of a comeback for Iovance Biotherapeutics (IOVA -0.08%)? Though the small-cap biotech has significantly trailed the broader market in the past five years, its shares are up by 50% since 2024 started. Iovance is making progress on several fronts (more on that below).It's no wonder that many investors are increasingly excited about the company's direction. But should long-term investors put their hard-earned money into this stock ...